Ryan Savitz insider trades: Dianthus Therapeutics (DNTH) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Ryan reports to the SEC
Open-market buys and sales
4 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Apr 9, 2026 | DNTH | ↓ Sell | 8,224 | $89.84 | $739K | Direct | Apr 10, 2026 (1d) |
| Mar 31, 2026 | DNTH | ↓ Sell | 114,367 | $83.00 | $9.5M | Direct | Apr 1, 2026 (1d) |
| Dec 4, 2025 | DNTH | ↓ Sell | 20,000 | $45.18 | $904K | Direct | Dec 5, 2025 (1d) |
| Sep 9, 2025 | DNTH | ↓ Sell | 20,000 | $35.00 | $700K | Direct | Sep 11, 2025 (2d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other DNTH insiders
Open-market trades in the last 12 months
About Ryan Savitz's insider trades
Ryan Savitz is EVP, CFO & Cbo at Dianthus Therapeutics (DNTH). Since Sep 9, 2025, Ryan has reported no open-market purchases and 4 sales worth $11.8M on SEC Form 4. In the last 12 months: 3 sales ($11.1M).
Their filings also include grants and awards (5 filings), option exercises (4 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every DNTH insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.